Kenvue Inc. (NYSE:KVUE) Shares Bought by Empirical Finance LLC

Empirical Finance LLC lifted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,127 shares of the company’s stock after buying an additional 786 shares during the quarter. Empirical Finance LLC’s holdings in Kenvue were worth $558,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in KVUE. Empowered Funds LLC grew its holdings in Kenvue by 19.2% during the 4th quarter. Empowered Funds LLC now owns 178,009 shares of the company’s stock worth $3,800,000 after acquiring an additional 28,638 shares in the last quarter. Farmers & Merchants Investments Inc. lifted its position in shares of Kenvue by 1.4% during the 4th quarter. Farmers & Merchants Investments Inc. now owns 73,910 shares of the company’s stock worth $1,578,000 after purchasing an additional 1,000 shares during the last quarter. Apollon Wealth Management LLC grew its stake in shares of Kenvue by 16.5% during the fourth quarter. Apollon Wealth Management LLC now owns 11,701 shares of the company’s stock worth $250,000 after purchasing an additional 1,653 shares in the last quarter. William Allan Corp increased its holdings in Kenvue by 16.3% in the fourth quarter. William Allan Corp now owns 44,032 shares of the company’s stock valued at $940,000 after buying an additional 6,173 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Kenvue by 10.1% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 218,273 shares of the company’s stock valued at $4,660,000 after buying an additional 19,973 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Up 2.1 %

Shares of Kenvue stock opened at $20.60 on Tuesday. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a market cap of $39.49 billion, a P/E ratio of 38.86, a PEG ratio of 2.16 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a fifty day moving average of $21.54 and a two-hundred day moving average of $22.00.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, analysts forecast that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.98%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is currently 154.72%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on KVUE shares. Barclays lowered their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group dropped their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Bank of America boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.